Insulin secretion in growth hormone-deficient adults: Effects of 24 months' therapy and five days' acute withdrawal of recombinant human growth hormone

Metabolism: Clinical and Experimental

Volumn 48, Issue 11, 1999, Pages 1387-1396

  Kamarudin, Norshinah ^b   Hew, Fen Lee ^b   Christopher, Michael ^b   Alford, Janet ^b   Rantzau, Christian ^b   Ward, Glenn ^b   Alford, Frank ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE;

ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; GROWTH HORMONE DEFICIENCY; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIPID BLOOD LEVEL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

EID: 13044313483     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90148-8     Document Type: Article

References (48)

1. Bergman RN: Towards physiological understanding of glucose tolerance: Minimal model approach (Lily Lecture). Diabetes 38:1512-1527, 1989
2. O'Neal DN, Kalfas A, Dunning PL, et al: The effect of three months of recombinant human growth hormone (rhGH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults. J Clin Endocrinol Metab 79:975-983, 1994
3. Hew FL, Koschmann M, Kreiger T, et al: Insulin tolerance test in patients with anterior pituitary hormone deficiency: Reduced insulin sensitivity. Endocrinol Metab 2:93-98, 1995
4. Weaver JU, Monson JP, Noonan K, et al: The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 80:153-159, 1995
5. Johansson JO, Fowelin J, Landin K, et al: Growth hormonedeficient adults are insulin resistant. Metabolism 44:1126-1129, 1995
6. Hew FL, Koschmann M, Christopher M, et al: Insulin resistance in growth hormone deficient adults: Defects in glucose utilisation and glycogen synthase activity. J Clin Endocrinol Metab 81:555-564, 1996
7. Beshyah SA, Henderson A, Niththyananthan R, et al: Metabolic abnormalities in growth hormone-deficient adults. II. Carbohydrate tolerance and lipid metabolism. J Endocrinol Metab 1:173-180, 1994
8. Beshyah SA, Henderson A, Niththyananthan R, et al: The effects of short and long term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 80:356-363, 1995
9. Rosén T, Bosaeus I, Tolli J, et al: Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 38:63-71, 1993
10. Merrimee TJ, Rabinowitz D, Rimoin DL, et al: Isolated human growth hormone deficiency. III. Insulin secretion in sexual ateliotic dwarfism. Metabolism 17:1005-1111, 1968
11. Rosén T, Johansson G, Hallgren P, et al: Beneficial effects of 12-month replacement therapy with recombinant human growth hormone to growth hormone deficient adults. Endocrinol Metab 1:55-66, 1994
12. Russell-Jones DL, Watts GF, Weissberger A, et al: The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin Endocrinol (Oxf) 41:345-350, 1994
13. Whitehead HM, Boreham C, McIirath EM, et al: Growth hormone treatment of adults with growth hormone deficiency: Results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) 36:45-52, 1992
14. Fowelin J, Attvall S, Bengtsson BA: Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 42:1443-1447, 1993
15. Christopher MJ, Hew FL, Oakley M, et al: Defects of insulin action and skeletal muscle glucose metabolism in growth hormonedeficient (GHD) adults persist following 24 month recombinant growth hormone (rhGH) therapy. J Clin Endocrinol Metab 83:1668-1681, 1998
16. Hew FL, O'Neal D, Kamarudin N, et al: Growth hormone deficiency and cardiovascular risk. Baillieres Clin Endocrinol Metab 12:199-216, 1998
17. Bengtsson BA, Eden S, Lonn L, et al: Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 76:309-317, 1993
18. Nielsen JH, Lernmark A, Ole D, et al: Effects of growth hormone on the endocrine pancreas, in Isaksson O (ed): Growth Hormone-Basic and Clinical Aspects. New York, NY, Elsevier Science, 1987, pp 227-237
19. Davidson M: Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 8:115-131, 1987
20. Pierluissi J, Campbell J: Metasomatotrophic diabetes and its induction: Basal insulin secretion and insulin release responses to glucose, glucagon, arginine and meals. Diabetologia 18:223-228, 1980
21. Sönksen PH, Greenwood FC, Ellis JP, et al: Changes of carbohydrate tolerance in acromegaly with progress of disease and in response to treatment. J Clin Endocrinol Metab 27:1418-1430, 1967
22. Lukaski HC, Johnson PE, Bolonchuk WW, et al: Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 41:810-817, 1985
23. Svendsen OL, Hassayer C, Bermann I, et al: Measurement of abdominal and intra-abdominal fat in postmenopausal women by dual energy x-ray absorptiometry and anthropometry: Comparison with computerised tomography. Int J Obes 17:45-51, 1993
24. Carey DG, Jenkins AB, Campbell LV, et al: Abdominal fat and insulin resistance in normal and overweight women; direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45:633-638, 1996
25. Phillips DIW, Clark PM, Hales CN, et al: Understanding oral glucose tolerance: Comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11:286-292, 1994
26. Hovorka R, Jones RH: How to measure insulin secretion. Diabetes Metab Rev 10:91-117, 1994
27. Lerner RL, Porte D: Relationships between intravenous glucose loads, insulin responses and glucose disappearance rate. J Clin Endocrinol Metab 33:409-417, 1971
28. Christopher MJ, Rantzau C, Ward GM, et al: Impact of variable insulinaemia and glycaemia on in-vivo glycolysis and glucose storage in dogs. Am J Physiol 29:E62-E71, 1994
29. Polonsky KS, Licinio-Paixao J, Given BD, et al: Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 77:98-105, 1986
30. O'Neal DN, Hew FL, Sikaris K, et al: Low-density lipoprotein particle size in hypopituitary adults on conventional hormone replacement therapy. J Clin Endocrinol Metab 81:2448-2454, 1996
31. Markussis V, Beshyah SA, Fisher C, et al: Detection of premature atherosclerosis by high-resolution ultrasonography in symptomfree hypopituitary adults. Lancet 340:1188-1192, 1992
32. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
33. McCulloch DK, Kahn SE, Schwatz MW, et al: Effect of nicotinic acid-induced insulin resistance on pancreatic β-cell function in normal and streptozocin-treated baboons. J Clin Invest 87:1395-1401, 1991
34. Beshyah SA, Gelding SV, Andres C, et al: B-cell function in hypopituitary adults before and during growth hormone treatment. Clin Sci 89:321-328, 1995
35. Ahmed S, Clark A, Matthews DR: Progressive decline of β-cell function in non-insulin dependent diabetes. Curr Opin Endocrinol Diabetes 4:300-307, 1997
36. Kahn SE, Prigeon RL, McCulloch DK, et al: Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: Evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993
37. Henriksen JE, Alford F, Handberg A, et al: Increased glucose effectiveness in normoglycaemic but insulin resistant relatives of patients with non-insulin dependent diabetes mellitus: A novel compensatory mechanism. J Clin Invest 94:1196-1204, 1994
38. Takano K, Hizuka N, Asakawa K, et al: Effects of sc administration of recombinant human insulin-like growth factor-I (IGF-I) on normal human subjects. Endocrinol Jpn 37:309-317, 1990
39. Prenki M, Corkey BE: Are the β-cell signalling molecules malonyl CoA and cytosolic long-chain acyl-CoA implicated in multiple tissue defects in obesity and NIDDM? Diabetes 45:273-283, 1996
40. Martin IK, Christopher MJ, Alford FP, et al: Distinctive but nonadditive effects of epinephrine and cortisol on determinants of glucose tolerance in dog. Am J Physiol 260:E148-E153, 1991
41. Henriksen JE, Alford FP, Ward GM, et al: The risk and mechanism of dexamethasone induced deterioration of glucose tolerance in non-diabetic first degree relatives of NIDDM patients. Diabetologia 40:1439-1448, 1997
42. Pestell R, Alford FP, Ramos R, et al: Insulin secretion, insulin sensitivity and glucose-mediated glucose disposal in thyrotoxicosis: A minimal model analysis. Clin Endocrinol (Oxf) 33:481-493, 1990
43. Bhasin S, Storer TW, Berman N, et al: Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 82:407-413, 1997
44. O'Sullivan AJ, Ho KK: A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 80:1783-1788, 1995
45. Jorgensen JOL, Møller J, Alberti KGMM, et al: Marked effects of sustained low growth hormone (GH) levels on day to day fuel metabolism: Studies in GH-deficient patients and healthy untreated subjects. J Clin Endocrinol Metab 77:1589-1596, 1993
46. Rosenbaum M, Gertner JM, Leibel RL: Effects of systemic growth hormone (GH) administration on regional adipose tissue distribution and metabolism in GH-deficient children. J Clin Endocrinol Metab 69:1274-1281, 1989
47. Rosenbaum M, Gertner JM, Gidfar N, et al: Effects of systemic growth hormone (GH) administration on regional adipose tissue in children with non-GH deficient short stature. J Clin Endocrinol Metab 75:151-156, 1992
48. Burman P, Johansson AG, Siegbahn A, et al: Growth hormone (GH) deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 82:550-555, 1997